2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
107
Carcinoma, Renal Cell
74
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
35
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Carcinoma, Hepatocellular
14
Colorectal Neoplasms
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
Sorafenib
5
Blood Specimen Collection
4
lenvatinib
3
sintilimab
2
pembrolizumab
2
ledipasvir, sofosbuvir drug combination
2
halofantrine
2
camrelizumab
2
atezolizumab
2
Liver Transplantation
2
Immunotherapy
2
Control Groups
2
Bevacizumab
2
Antibodies
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
rubitecan
1
repotrectinib
1
pevonedistat
1
ozanimod
1
linifanib
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Everolimus
×
Clear all
NCT01423708
2012-07-18
EPOCAL
Azienda Ospedaliera di Padova
Phase 2
Unknown
117 enrolled